Revised outcome of the board meeting for discussing and approving the financial results for the year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
iSERA Lifesciences Limited (formerly Covidh Technologies Limited) reported audited standalone financial results for FY2026. Revenue from operations surged to ₹135.50 Lakhs from ₹26.52 Lakhs in FY2025, representing over 400% growth. Profit after tax increased to ₹25.94 Lakhs from ₹11.81 Lakhs, up approximately 120%. The company raised ₹808.56 Lakhs through a rights issue (80,85,550 equity shares at ₹10 each) and reported negative operating cash flow of ₹535.42 Lakhs. Cash and cash equivalents improved significantly to ₹286.62 Lakhs from ₹2.08 Lakhs. Operating profit margin compressed from 52.38% to 24.83%, while net profit margin declined from 44.53% to 19.14%. The auditor issued an unmodified (clean) opinion with no qualifications.
The company showed strong top-line and bottom-line growth, but operating cash flow remains negative despite the rights issue proceeds. The significant increase in share capital (from ₹3.23 Lakhs to ₹84.09 Lakhs) has diluted earnings per share from ₹3.65 to ₹0.74. The clean audit opinion and improved cash position are positive signals for investors.